Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM

NCT06492330 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Obesity
Diabetes Mellitus, Type 2

Interventions

DRUG: CS0159
DRUG: CS0159 placebo

Sponsor

Shanghai Jiao Tong University School of Medicine